A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
← catalyst calendarNCT03873402 · readout in 204 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
437actual
Sites
78
Countries
Argentina, Austria, Chile +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-21 | actual | When the study began enrolling |
| Primary completion | 2027-03-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-11 | estimated | The whole study's end, after follow-up |
| First posted | 2019-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Renal Cell Carcinoma
Interventions
- Biological: Nivolumab — also filed as Opdivo
- Biological: Ipilimumab — also filed as Yervoy
- Other: Ipilimumab placebo
Primary outcomes
what the primary-completion date above is the date OFProgression free survival (PFS) by blinded independent central review (BICR)
measured Up to 34 months
Objective response rate (ORR) by BICR
measured Up to 23 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed